Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.66 |
| ▸ | MAOA | P21397 | 10/20 | 0.66 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5211642 | 0.90 | MAOB (0.61) | MAOBMAOAHRH3ALOX5 | |
| SCHEMBL3875255 | 0.89 | MAOA (0.68) | MAOBMAOAHRH3ALOX5 | |
| Hydrochloric Acid SCHEMBL3902331 | 0.88 | MAOA (0.66) | MAOBMAOAHRH3ALOX5 | |
| SCHEMBL15897930 | 0.86 | MAOA (0.50) | MAOBMAOAHRH3 | |
| SCHEMBL15898249 | 0.84 | MAOA (0.49) | MAOBMAOA | |
| SCHEMBL15897864 | 0.82 | MAOA (0.47) | MAOBMAOAHRH3 | |
| Hydrochloric Acid SCHEMBL3902342 | 0.82 | MAOB (0.59) | MAOBMAOAHRH3ALOX5 | |
| SCHEMBL31444064 | 0.81 | MAOA (0.64) | MAOBMAOAHRH3 | |
| SCHEMBL3077665 | 0.81 | HRH3 (0.67) | MAOBMAOAHRH3ALOX5 | |
| SCHEMBL13598169 | 0.81 | MAOB (0.58) | MAOBMAOAHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3252050-B1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-02-26 | — | — | EP | disclosed |
| EP-3252050-B1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-02-26 | — | — | EP | disclosed |
| EP-3222620-B1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) | 2019-11-20 | — | — | EP | disclosed |
| US-10385026-B2 | Phthalazinones and isoquinolinones as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-20 | — | — | US | disclosed |
| US-10385026-B2 | Phthalazinones and isoquinolinones as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-20 | — | — | US | disclosed |
| US-10246443-B2 | Cyanoquinoline derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2019-04-02 | — | — | US | disclosed |
| US-20180162823-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162823-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-14 | — | — | US | disclosed |
| EP-2945943-B1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-2945943-B1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-2581372-A1 | CYANOQUINOLINE DERIVATIVES | Tianjin Hemay Bio-Tech Co., Ltd. (CN) | 2013-04-17 | — | — | EP | disclosed |
| WO-2011153942-A1 | CYANOQUINOLINE DERIVATIVES | 天津和美生物技术有限公司 (CN) | 2011-12-15 | — | — | WO | disclosed |
| CN-101309904-A | 1- (1H-indol-1-yl) -3- (methylamino) -1-phenylpropan-2-ol derivatives and related compounds as monoamine reuptake modulators for the treatment of vasomotor symptoms (VMS) | WYETH CORP (US) | 2008-11-19 | — | — | CN | disclosed |
| EP-1931631-A1 | 1- (1H- INDOL- 1-YL) -3- (METHYLAMINO) -1- PHENYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | Wyeth a Corporation of the State of Delaware (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007041023-A1 | 1- (1H- INDOL- 1-YL) -3- (METHYLAMINO) -1- PHENYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | WYETH (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070072897-A1 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2007-03-29 | — | — | US | disclosed |
| US-5736534-A | HYPERPROLIFERATIVE DISEASES; INHIBITORS OF PROTEIN-TYROSINE KINASES SUCH AS EPIDERMAL GROWTH FACTOR RECEPTOR; BRAIN, LUNG, BREAST CANCER; PSORIASIS AND BENIGN PROSTATE HYPERPLASIA | PFIZER INC. (US) | 1998-04-07 | — | — | US | disclosed |
| CN-1141633-A | 4-heterocyclic substituted quinazoline derivatives, process for their preparation and their use as anticancer agents | PFIZER (US) | 1997-01-29 | — | — | CN | disclosed |
| EP-0746554-A1 | 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | PFIZER INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| WO-1995023141-A1 | 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | PFIZER INC. (US) | 1995-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072897-A1 | Phenylaminopropanol derivatives and methods of their use | COMT, PNMT, GLS | MAOB 18/4885MAOA 13/4885HRH3 1760/4885 |
| US-10246443-B2 | Cyanoquinoline derivatives | CBR3, CYP3A4, CDK1 | MAOB 1410/4885MAOA 2022/4885HRH3 699/4885 |
| US-20180162823-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | MYLK, MYLK2, ROCK1 | MAOB 2507/4885MAOA 2604/4885HRH3 2801/4885 |
| US-10385026-B2 | Phthalazinones and isoquinolinones as rock inhibitors | MYLK, MYLK2, ROCK1 | MAOB 2507/4885MAOA 2604/4885HRH3 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.